Mogamulizumab: 2 birds, 1 stone

Blood

Volumn 125, Issue 12, 2015, Pages 1847-1848

  Wilcox, Ryan A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR4; MOGAMULIZUMAB; CCR4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ALTERNATIVE MEDICINE; ARTICLE; CANCER CHEMOTHERAPY; CELL HOMING; CELL SURVIVAL; DENDRITIC CELL; DISEASE ACTIVITY; DRUG TARGETING; DRUG TOLERABILITY; GAIN OF FUNCTION MUTATION; HUMAN; LYMPHOCYTE MIGRATION; MACROPHAGE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; SEZARY SYNDROME; TREATMENT RESPONSE; FEMALE; IMMUNOLOGY; LYMPHOMA, T-CELL, CUTANEOUS; MALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; RECEPTORS, CCR4;

EID: 84925358053     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-02-625251     Document Type: Article

References (10)

1. Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883-1889.
2. Hughes CF, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71-81.
3. Iqbal J, Wright G, Wang C, et al; Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915-2923.
4. Wang T, Feldman AL, Wada DA, et al. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014;123(19):3007-3015.
5. Nakagawa M, Schmitz R, Xiao W, et al. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med. 2014;211(13):2497-2505.
6. Ni X, Jorgensen JL, Goswami M, et al. Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome. Clin Cancer Res. 2015;21(2):274-285.
7. Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157-1163.
8. Wilcox RA, Tamada K, Strome SE, Chen L. Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol. 2002;169(8):4230-4236.
9. Kohrt HE, Houot R, Goldstein MJ, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423-2432.
10. Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114(10):2149-2158.